Clinical Trial Update: Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating dose-dense temozolomide plus lapatinib for recurrent ependymoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Spinal Cord Tumors

Drugs mentioned

• Lapatinib (Lapatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Brain Tumors, Spinal Cord Tumors | Phase 2 | Status: COMPLETED | Results posted: 2019-03-22